Malta - English - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - oxaliplatin - concentrate for solution for infusion - oxaliplatin 5 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - oxaliplatin - concentrate for solution for infusion - oxaliplatin 5 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - oxaliplatin - concentrate for solution for infusion - oxaliplatin 5 mg/ml - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - oxaliplatin - concentrate for solution for infusion - 5 milligram(s)/millilitre - platinum compounds; oxaliplatin

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - oxaliplatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - oxaliplatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer.,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for: the treatment of patients with advanced oesophagogastric cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer.,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for: the treatment of patients with advanced oesophagogastric cancer

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections - oxaliplatin is indicated for adjuvant treatment of stage iii (duke?s c) colon cancer, in combination with fluoropyrimidine agent.,oxaliplatin in combination with fluorouracil and folinic acid is indicated for the treatment of advanced colorectal cancer.,oxaliplatin in combination with capecitabine, with or without bevacizumab, is indicated for the treatment of patients with metastatic colorectal cancer.,oxaliplatin in combination with epirubicin and either capecitabine or fluorouracil, is indicated for: the treatment of patients with advanced oesophagogastric cancer

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - oxaliplatin - injection, solution, concentrate - 5.0 mg / ml